Search BNGO
Bionano Genomics, Inc.
NasdaqCM · CIK 1411690
Last close1.48
Daily change-0.09 (-5.73%)
10 Years gain-99.96%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BNGO · STANDARD
SIC 3826 · Laboratory Analytical Instruments · Fiscal year end 1231
Fundamental
54.6Momentum
100.0Acceleration
100.0Confidence
82.0Annual Revenue9
Quarterly Revenue33
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth8.0 / 25
Quality18.7 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators2.9 / 5
Signals
Gross margin expansionGross margin improved by 50.1126 percentage points.
Operating leverageOperating margin improved by 237.1254 percentage points.
ROIC expansionROIC improved by 88.514 percentage points.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 328.582%.
Key Metrics
Revenue Growth TTM-0.39%OK
Revenue CAGR 3Y0.84%OK
Gross Margin49.77%OK
Operating Margin-108.62%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-89.92%OK
Incremental Operating Margin 3Y838.05%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y328.58%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $28.51M | $13.19M | -$33.34M | -$16.35M | n/a | 46.25% | -116.95% | n/a | -103.17% | 5.45M |
| 2025 FY Dec 31, 2024 | $30.78M | $380,000.00 | -$103.98M | -$68.92M | n/a | 1.23% | -337.87% | n/a | -297.17% | 1.27M |
| 2024 FY Dec 31, 2023 | $36.12M | $9.57M | -$215.25M | -$125.18M | n/a | 26.49% | -595.98% | n/a | -205.37% | 569,000 |
| 2023 FY Dec 31, 2022 | $27.80M | $5.95M | -$131.70M | -$124.82M | n/a | 21.38% | -473.7% | n/a | -93.43% | 28.92M |
| 2022 FY Dec 31, 2021 | $17.98M | $3.87M | -$77.10M | -$71.93M | n/a | 21.55% | -428.79% | n/a | -122.47% | 276.78M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $28.96M | sum latest 4 fiscal quarters Revenue | OK | 0001411690-26-000044, 0001411690-25-000093 |
| Revenue Growth TTM | -0.39% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001411690-26-000044, 0001411690-25-000093 |
| Revenue CAGR 3Y | 0.84% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001411690-26-000007 |
| Revenue CAGR 5Y | 27.37% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001411690-26-000007 |
| Gross Profit CAGR 3Y | 30.41% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001411690-26-000007 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001411690-26-000044, 0001411690-25-000093 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 49.77% | Gross Profit / Revenue | OK | 0001411690-26-000044, 0001411690-25-000093 |
| Operating Margin | -108.62% | Operating Income / Revenue | OK | 0001411690-26-000044, 0001411690-25-000093 |
| ROIC | -89.92% | NOPAT / Average Invested Capital | OK | 0001411690-26-000044, 0001411690-25-000093 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001411690-26-000044 |
| Current Ratio | 2.48x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.51 | Revenue / Diluted Shares | OK | 0001411690-26-000044, 0001411690-25-000093 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |